Control vs. Strategy: Inside Nano Dimension's High-Stakes Boardroom Brawl

WALTHAM, Mass. – July 09, 2026 – Nano Dimension, a company navigating a profound strategic transformation, finds itself at the epicenter of a contentious proxy battle that will define its future. The advanced manufacturing firm is locked in a public and increasingly acrimonious struggle with activist investor Murchinson Ltd., culminating in an Extraordinary General Meeting (EGM) on July 31 that forces shareholders to choose between the incumbent board's vision and the activist's bid for control.

At stake is not just the composition of the board, but the very direction of a company attempting to pivot from its manufacturing roots toward the high-growth sector of AI-powered diagnostics. The dispute lays bare the friction between corporate leadership steering a long-term strategy and activist investors demanding more immediate returns and a greater say in governance.

The Anatomy of a Proxy War

The conflict centers on Murchinson's proposal to oust three of Nano Dimension’s five directors and install its own slate of nominees. In a letter to shareholders, Nano Dimension's Board frames this as an all-or-nothing power grab. The Board argues that if Murchinson's proposal succeeds, the activist would gain "100% of the Board" through its new appointees and an existing director who "remains aligned with and loyal to Murchinson." The situation is further complicated by the public disclosure from Andy Sriubas, a current independent director, that he will not continue to serve if Murchinson gains control.

This proxy contest, according to the Board, is the direct result of its rejection of a series of "inappropriate, self-interested demands" from Murchinson. The company detailed several of these demands, painting a picture of an activist seeking to extract value for itself at the expense of other shareholders. These rejected demands include:

• A $15 million reimbursement for Murchinson's prior activism campaigns and litigation costs, which the Board denied, stating Murchinson failed to provide adequate supporting documentation.
• A demand for the company to engage Murchinson as its litigation advisor under an agreement with significant fees, a proposal the Board rejected due to what it called "significant conflicts of interest."
• An insistence that Board members, including those originally nominated by Murchinson, take direction from the activist on corporate matters, which the Board deemed inconsistent with a director’s fiduciary duty to act independently.

This standoff follows a failed attempt at a settlement in April 2026, where the Board claims Murchinson "rejected all reasonable proposals" from the company. Murchinson, for its part, has been vocal about its dissatisfaction with what it calls the company's "troubling history of underperformance, poor corporate governance and value-destructive decisions."

An Activist with a History

Murchinson Ltd., a Toronto-based alternative asset management firm holding approximately 7.7% of Nano's shares, is no stranger to aggressive tactics. The firm's public campaign against Nano Dimension is rooted in its belief that the Board is mismanaging capital and destroying shareholder value. However, Nano Dimension's Board is actively using Murchinson's own past to cast doubt on its motives.

The Board's letter to shareholders prominently highlights Murchinson's prior regulatory troubles, specifically a 2021 SEC Administrative Proceeding. Research confirms that the SEC charged Murchinson and its principal, Marc Bistricer, with violations related to short-selling rules. The firm was found to have provided incorrect order-marking information for a client's sale orders, leading to violations of Regulation SHO. The case resulted in a settlement where Murchinson and its affiliates paid approximately $8.9 million in disgorgement, interest, and penalties. Nano Dimension's Board argues this history is "consistent with Murchinson's misconduct in other circumstances."

This history forms a critical backdrop to the current fight, allowing the Board to question whether Murchinson is a genuine agent for shareholder value or a self-interested actor with a track record of regulatory infractions. Murchinson has countered with its own governance-focused proposals, including amendments to declassify the board and limit the use of defensive measures like poison pills, arguing these changes are necessary to empower shareholders.

A Company in Transition

Beyond the boardroom drama, Nano Dimension is a company in deep transition. The current Board states it inherited "several irreversible decisions" from prior leadership, including agreements to acquire Desktop Metal, Inc. and Markforged Holding Corporation that were "hastily negotiated." This legacy has been a point of contention for Murchinson, which has criticized past capital allocation.

In response, the current Board initiated a strategic review in 2025 to streamline operations and find a more compelling use for its capital base. The centerpiece of this new strategy is a potential business combination with Infinite Epigenetics, a move designed to create a publicly traded, AI-powered health and diagnostics company. The Board, with assistance from advisors Houlihan Lokey and Guggenheim Securities, believes this transaction represents the "best prospect for maximizing shareholder value."

Murchinson vehemently disagrees, labeling the Infinite Epigenetics deal "deeply flawed" and a "misallocation of corporate resources" that moves the company too far from its core competencies. This strategic divergence is the fundamental chasm between the two sides. Complicating matters further, Nano Dimension has also received an unsolicited, all-cash merger proposal from Tang Capital, which the Board states it is evaluating through a "disciplined process."

Governance and the Path Forward

The upcoming EGM is not a referendum on the Infinite Epigenetics deal or the Tang Capital offer. As the Board's letter emphasizes, it is a vote on who should be entrusted to make those decisions. "It is a vote on whether shareholders believe the current Board should continue to exercise independent judgment, oversee the Company, and continue a structured review of strategic alternatives in the best interests of all shareholders," the company stated.

If the Board proceeds with a definitive agreement with Infinite Epigenetics, it has committed to providing shareholders with extensive information and holding a separate vote on the binding transaction in the fall. This structure, the Board argues, "preserves full shareholder choice while ensuring a disciplined and transparent process."

Shareholders are now left to weigh two starkly different narratives. One is of an independent board attempting to navigate a complex strategic pivot while fending off a self-interested activist with a checkered past. The other is of an underperforming company whose leadership is pursuing a risky, unrelated venture, requiring an activist's intervention to restore discipline and protect shareholder value. The vote on July 31 will determine which narrative prevails and who will be in command as Nano Dimension attempts to shape its next chapter.